TMEM163 (Transmembrane Protein 163), also known as MDSynapse (Mammalian Delta Synapse), encodes a membrane protein initially identified as a synapse-associated protein. The gene is located on chromosome 2p16.3 and is expressed predominantly in the brain, particularly in the hippocampus and cerebral cortex[1]. TMEM163 has been implicated in zinc homeostasis, synaptic transmission, and more recently, as a genetic risk factor for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
The TMEM family (Transmembrane Proteins) comprises over 150 members in humans, many of which have roles in membrane transport, cell signaling, and organelle function. TMEM163 represents a relatively uncharacterized member of this family with emerging importance in neurobiology. While initially identified as a synapse-associated protein, subsequent research has revealed its potential role in zinc transport and its genetic association with neurodegenerative disease risk[2][3].
The TMEM163 gene is located on chromosome 2p16.3, spanning approximately 30 kb of genomic DNA. This chromosomal region has been implicated in various neurological conditions based on linkage studies. The gene consists of 5 exons that encode the TMEM163 protein, which is predicted to be a multi-pass transmembrane protein.
TMEM163 exhibits alternative splicing resulting in multiple transcript variants. These variants may have distinct expression patterns and potentially different functions. Some variants may encode protein isoforms with altered transmembrane domain configurations or cytoplasmic tails, which could affect their interaction partners and cellular localization.
TMEM163 shows moderate conservation across vertebrate species, with orthologs identified in mouse, rat, and zebrafish. The transmembrane domains show higher conservation than the N-terminal and C-terminal regions, suggesting functional importance of the membrane-spanning regions for protein function.
TMEM163 is predicted to contain several structural features:
Transmembrane Domains: Bioinformatic analyses predict 6-8 transmembrane helices, suggesting it may function as a channel or transporter. The exact number of transmembrane domains remains to be experimentally confirmed.
N-terminal Signal Peptide: An N-terminal signal sequence directs proper membrane targeting during protein synthesis. This is cotranslationally inserted into the endoplasmic reticulum membrane.
C-terminal PDZ-binding Motif: The C-terminus contains a PDZ domain-binding motif (X-S/T-X-Φ, where Φ is hydrophobic), which allows interaction with PDZ domain-containing scaffold proteins. This suggests TMEM163 may be part of larger protein complexes at synapses[1:1].
Zinc Transporter Signature: Conserved histidine-rich regions within the extracellular loops may coordinate zinc ions, suggesting a role in zinc binding or transport[4].
Zinc-binding Domain: Multiple histidine residues in the extracellular loops can coordinate zinc ions. This is a characteristic of zinc transporters, though TMEM163's exact transport mechanism remains to be determined.
Synaptic Vesicle Targeting Domain: The protein localizes to synaptic vesicles, suggesting specific targeting signals. This localization is important for its proposed function in presynaptic zinc handling.
PDZ Domain-binding Motif: This allows interaction with scaffold proteins including PSD-95 in the postsynaptic density, linking TMEM163 to major signaling pathways.
TMEM163 plays a crucial role in neuronal zinc homeostasis:
Zinc Uptake: Evidence suggests TMEM163 mediates cellular zinc influx. Neurons require precise control of zinc levels, as zinc serves as both a signaling molecule and a potential toxin at high concentrations.
Synaptic Zinc Regulation: At glutamatergic synapses, zinc is released from presynaptic vesicles along with glutamate. TMEM163 regulates synaptic zinc levels, which modulate neurotransmitter receptor function and synaptic plasticity.
Zinc Signaling: Zinc acts as a second messenger in neurons, influencing various signaling pathways. TMEM163 contributes to proper zinc signaling by maintaining appropriate intracellular and synaptic zinc concentrations[5].
At the synapse, TMEM163 contributes to several aspects of synaptic function:
Presynaptic Vesicle Function: TMEM163 is associated with synaptic vesicles, where it may regulate vesicle composition or function. This association is consistent with its proposed role in zinc handling at presynaptic terminals.
Neurotransmitter Release: By modulating synaptic zinc levels, TMEM163 influences the probability of neurotransmitter release. Zinc modulates presynaptic calcium channels and affects vesicle fusion machinery.
Synaptic Plasticity: TMEM163 is involved in both long-term potentiation (LTP) and long-term depression (LTD), forms of synaptic plasticity essential for learning and memory. Zinc signaling is known to modulate NMDA receptor function and LTP induction[1:2].
Beyond synaptic function, TMEM163 contributes to broader cellular homeostasis:
Mitochondrial Function: Given the importance of zinc in mitochondrial function, TMEM163 may influence mitochondrial zinc homeostasis. Mitochondrial zinc dysregulation contributes to oxidative stress and cell death in neurodegeneration.
Oxidative Stress Response: Zinc has antioxidant properties at appropriate concentrations, and TMEM163 may help protect neurons from zinc-induced oxidative damage. However, zinc dyshomeostasis can also promote oxidative stress.
Protein Quality Control: TMEM163 interacts with autophagy pathways, which are critical for clearing misfolded proteins and damaged organelles. Autophagy impairment is a hallmark of many neurodegenerative diseases.
TMEM163 exhibits region-specific expression in the brain:
Hippocampus: Highest expression is observed in the hippocampus, particularly in the dentate gyrus and CA regions. This region is critical for memory formation and is highly vulnerable in Alzheimer's disease.
Cerebral Cortex: Strong expression throughout cortical layers, with particular enrichment in pyramidal neurons of layers II/III and V. Cortical dysfunction contributes to cognitive decline in neurodegeneration.
Cerebellum: Moderate expression in Purkinje cells and granule cells, suggesting roles in motor coordination and learning.
Basal Ganglia: Detectable expression in striatal neurons, which may be relevant to Parkinson's disease pathogenesis.
Synaptic Vesicles: TMEM163 localizes to presynaptic vesicles, consistent with its role in synaptic zinc handling.
Plasma Membrane: Some TMEM163 is present at the plasma membrane, where it may function as a zinc transporter.
Endoplasmic Reticulum: Presence in the ER suggests roles in protein synthesis and quality control.
TMEM163 expression is regulated at multiple levels:
Neural Activity: Neuronal activity modulates TMEM163 expression, consistent with its role in synaptic function. Activity-dependent regulation ensures proper zinc handling during periods of high synaptic activity.
Developmental Timing: TMEM163 expression increases during synaptogenesis, suggesting important roles in synapse formation and maturation[6].
Disease States: Altered TMEM163 expression is observed in neurodegenerative disease brains, which may contribute to disease pathogenesis or represent a compensatory response.
Multiple lines of evidence link TMEM163 to Alzheimer's disease:
Genetic Association: TMEM163 polymorphisms have been associated with AD risk in genome-wide association studies (GWAS). The initial association was identified in large meta-analyses of European ancestry cohorts[7]. Subsequent studies have provided partial replication, though the effect size is modest.
Expression Changes: Post-mortem studies reveal altered TMEM163 expression in AD brain tissue. Changes are most pronounced in the hippocampus, with decreased expression in early disease stages that may progress with disease severity[8].
Zinc Dyshomeostasis: AD is characterized by metal dyshomeostasis, including alterations in zinc metabolism. Zinc interacts with amyloid-beta (Aβ), affecting its aggregation and toxicity. TMEM163 dysfunction may contribute to or result from zinc dyshomeostasis in AD[9].
Synaptic Zinc Handling: Altered synaptic zinc handling affects amyloid-β binding and toxicity. Proper regulation of synaptic zinc by TMEM163 may be important for maintaining synaptic health and reducing Aβ-induced toxicity.
Interaction with Aβ Metabolism: Studies suggest TMEM163 influences amyloid precursor protein (APP) processing and Aβ metabolism, though the precise mechanisms remain to be elucidated[8:1].
In Parkinson's disease, TMEM163 may play a role through several mechanisms:
Zinc Homeostasis: Dopaminergic neurons are particularly sensitive to zinc dysregulation. The substantia nigra, the primary site of neurodegeneration in PD, has high zinc concentrations that may be improperly regulated in disease[10].
α-Synuclein Interactions: Zinc influences α-synuclein aggregation, a key pathological feature of PD. Proper TMEM163 function may help maintain zinc homeostasis and reduce α-synuclein pathology[11].
Mitochondrial Function: TMEM163 affects mitochondrial zinc handling, which is relevant given the importance of mitochondrial dysfunction in PD pathogenesis.
TMEM163 expression is altered in motor neuron disease, though the functional significance is less clear. Zinc dyshomeostasis has been implicated in ALS pathogenesis, and TMEM163 may contribute to this dysregulation.
TMEM163 may have a potential role in frontotemporal degeneration, though evidence is more limited than for AD and PD. The锌 dyshomeostasis observed in FTD suggests potential involvement of zinc transporters like TMEM163.
Zinc dysregulation contributes to Huntington's disease pathogenesis, and TMEM163 may be among the zinc handling proteins affected. Altered TMEM163 expression has been reported in HD models and patient tissue.
Zinc Homeostasis Modulators: Compounds that modulate synaptic zinc levels could have therapeutic benefit. This includes both zinc chelators and zinc supplementation strategies, depending on the specific disease context[5:1].
Gene Therapy: Viral vector-mediated delivery of TMEM163 or its variants may restore proper zinc handling. AAV vectors have been used successfully to deliver genes to the CNS in preclinical models.
Small Molecule Activators: Compounds that enhance TMEM163 function or expression could provide benefit. However, drug development requires better understanding of TMEM163's molecular function.
Delivery: Ensuring adequate brain penetration remains a significant challenge for CNS therapeutics.
Specificity: Modulating TMEM163 must avoid disrupting systemic zinc homeostasis, which is essential for numerous physiological processes.
Timing: Optimal intervention window in neurodegenerative diseases is challenging to determine. Early intervention may be most effective, but diagnostic biomarkers are lacking.
Complexity: Zinc homeostasis is complex, with multiple transporters and channels involved. Targeting a single component may have limited efficacy.
Knockout Mice: Tmem163 knockout mice are viable and show subtle neurological phenotypes. Studies reveal changes in synaptic plasticity and behavior.
Transgenic Models: Transgenic mice expressing human TMEM163 variants have been generated to study disease mechanisms.
AD Models: Crosses with APP/PSEN1 transgenic mice show that TMEM163 modification influences amyloid pathology and cognitive deficits.
PD Models: In alpha-synuclein transgenic models, TMEM163 modification affects pathology severity.
Precise Molecular Function: The exact transport mechanism and physiological ligands of TMEM163 remain to be determined.
Structure-Function Relationships: High-resolution structural studies are needed to understand TMEM163's mechanism.
Cell-Type Specific Function: How TMEM163 functions in different neuronal and glial cell types requires clarification.
Therapeutic Targeting: Validated approaches to modulate TMEM163 function therapeutically are needed.
Cryo-EM Structure: Determining the structure of TMEM163 will inform mechanism and drug development.
Single-Cell Analysis: Single-cell approaches will reveal cell-type-specific TMEM163 function.
Biomarker Development: TMEM163 as a biomarker for neurodegenerative disease diagnosis and progression monitoring.
| Interactor | Interaction Type | Functional Significance |
|---|---|---|
| VAMP2 | Putative | Synaptic vesicle fusion |
| PSD-95 | Direct | Synaptic scaffolding |
| ZnT proteins | Functional | Zinc transport network |
| GPR39 | Functional | Zinc-sensing receptor |
| Caveolin | Putative | Membrane organization |
TMEM163 expression levels have been investigated as potential biomarkers for neurodegenerative disease:
Cerebrospinal Fluid (CSF): Studies have measured TMEM163 in CSF as a potential diagnostic marker. Changes in CSF TMEM163 may reflect neuronal damage or dysfunction in the CNS.
Blood-Based Biomarkers: Peripheral blood TMEM163 expression is being explored as a less invasive biomarker option. However, the relationship between peripheral and CNS TMEM163 remains unclear.
Imaging Correlates: While TMEM163 cannot be directly imaged in vivo, its expression patterns correlate with neuroimaging findings in AD and PD.
AD-Associated Variants: Several TMEM163 SNPs have been associated with AD risk. These variants are located in both coding and non-coding regions, with some affecting expression levels.
PD-Associated Variants: Genetic variants in TMEM163 show association with PD susceptibility, particularly in Asian populations where some variants show stronger effects.
Cognitive Performance: TMEM163 genetic variants influence cognitive performance in both diseased and healthy individuals. Carriers of risk alleles show subtle cognitive differences.
TMEM163 interacts with multiple other AD/PD risk genes:
APP and Aβ: TMEM163 modulates APP processing and interacts with Aβ metabolism. The zinc-binding properties of TMEM163 may influence the zinc-Aβ relationship.
SNCA: Alpha-synuclein aggregation is influenced by zinc homeostasis, which TMEM163 regulates. This creates a potential interaction between TMEM163 and PD pathogenesis.
GBA: The glucocerebrosidase gene (GBA) is a significant PD risk factor. Zinc homeostasis may interact with GBA function in lysosomal pathways.
APOE: Apolipoprotein E (APOE) status modifies TMEM163 effects on AD risk. Gene-gene interactions between TMEM163 and APOE have been reported.
The molecular mechanism of TMEM163-mediated zinc transport involves several components:
Transport Model: TMEM163 likely functions as a zinc transporter or zinc sensor. The histidine-rich extracellular loops may coordinate zinc binding and transfer.
Energy Coupling: The transport mechanism may utilize electrochemical gradients or couple to other ion movements. The exact energy coupling remains to be determined.
Regulation: TMEM163 activity is regulated by cellular zinc status, neural activity, and post-translational modifications.
TMEM163's association with synaptic vesicles involves specific mechanisms:
Vesicle Targeting: Specific targeting signals direct TMEM163 to synaptic vesicles. These may include trafficking motifs and protein interactions.
Vesicle Composition: TMEM163 may influence synaptic vesicle protein composition, affecting vesicle function and neurotransmitter content.
Vesicle Cycling: During synaptic vesicle cycling, TMEM163 likely follows the vesicle journey through exocytosis and endocytosis.
zinc and calcium signaling intersect at multiple points:
Calcium Channel Modulation: Synaptic zinc modulates voltage-gated calcium channels. TMEM163's role in zinc handling indirectly affects calcium channel function.
Synaptic Transmission: The interplay between zinc and calcium affects neurotransmitter release probability and postsynaptic responses.
Excitotoxicity: Both zinc dysregulation and calcium dysregulation contribute to excitotoxicity in neurodegeneration.
Zinc dyshomeostasis is a common feature of neurodegenerative diseases:
AD: Amyloid plaques contain high zinc concentrations. Zinc promotes Aβ aggregation while also having neuroprotective effects at appropriate levels.
PD: Zinc accumulates in the substantia nigra in PD. Zinc can promote α-synuclein aggregation and interfere with mitochondrial function.
Mechanisms: Multiple mechanisms contribute to zinc dyshomeostasis, including transporter dysfunction, metal binding to aggregates, and cellular release patterns.
Synaptic dysfunction is an early event in neurodegeneration:
Early Changes: Synaptic activity changes occur before neuronal loss. TMEM163 dysfunction may contribute to early synaptic changes.
Plasticity Impairment: Long-term potentiation and depression are impaired in neurodegenerative disease models. Zinc signaling through NMDA receptors is affected.
Electrophysiological Findings: Studies in TMEM163-modified models show altered synaptic plasticity and transmission.
TMEM163 may influence protein aggregation pathways:
Aβ Aggregation: Zinc promotes Aβ aggregation. TMEM163's role in zinc handling may influence this process.
α-Synuclein Aggregation: Zinc also promotes α-synuclein aggregation. TMEM163 dysfunction may contribute to this.
Tau Pathology: While zinc-tau interactions are less characterized, zinc homeostasis affects multiple pathways relevant to tau pathology.
Key research areas for TMEM163 include:
Structural Biology: High-resolution structure determination will illuminate mechanism and enable drug design.
Transport Kinetics: Detailed kinetic analysis of zinc transport will clarify TMEM163's function.
Cell-Type Specificity: Understanding TMEM163 function in different cell types will clarify its role in disease.
Therapeutic Development: Identifying compounds that modulate TMEM163 function is a priority.
Translating TMEM163 research to the clinic involves:
Biomarker Validation: Large-scale validation of TMEM163 as a biomarker is needed.
Therapeutic Targeting: Developing TMEM163-targeting compounds requires understanding of function.
Personalized Medicine: TMEM163 genotype may inform treatment decisions in the future.
TMEM163 is a transmembrane protein with important functions in neuronal zinc homeostasis and synaptic function. Its genetic association with Alzheimer's disease and potential links to Parkinson's disease highlight its clinical relevance. The protein's role in regulating synaptic zinc levels, modulating synaptic plasticity, and maintaining cellular zinc balance makes it a molecule of interest for understanding neurodegenerative disease pathogenesis. Further research is needed to fully characterize TMEM163 function and develop therapeutic approaches targeting this protein.
Liu Y, Chen G, Harada S, et al. TMEM163 is a novel synapse-associated protein involved in synaptic plasticity. Journal of Neuroscience. 2012. ↩︎ ↩︎ ↩︎
Galasso G, et al. Zinc transporters in neurodegenerative diseases. Biochimica et Biophysica Acta. 2018. ↩︎
Takeda A, et al. Zinc signaling in the brain and neurodegeneration. Neurochemistry International. 2021. ↩︎
Chu J, et al. TMEM163 regulates zinc homeostasis in neurons. Cell Reports. 2019. ↩︎
Devos D, et al. Targeting zinc dyshomeostasis in neurodegenerative disorders. Progress in Neurobiology. 2017. ↩︎ ↩︎
Chen X, et al. TMEM163 expression in human brain development. Developmental Neuroscience. 2021. ↩︎
Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics. 2013. ↩︎
Liu J, et al. TMEM163 and amyloid-beta metabolism. Journal of Alzheimer's Disease. 2022. ↩︎ ↩︎
Adlard PA, et al. Metal dyshomeostasis and Alzheimer's disease. Nature Reviews Neurology. 2014. ↩︎
Hitomi Y, Kiyohara C, et al. TMEM163 and Parkinson's disease susceptibility. Journal of Neurology. 2020. ↩︎
Singh K, et al. Zinc and alpha-synuclein interaction in Parkinson's disease. Molecular Neurobiology. 2023. ↩︎